Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jakob Landau

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Biomedicines|November 27, 2025
Employing an Artificial Intelligence Platform to Enhance Treatment Responses to GLP-1 Agonists by Utilizing Metabolic Variability Signatures Based on the Constrained Disorder PrincipleJakob Landau, Yariv Tiram, Yaron Ilan
Cancer Research|October 20, 2022
Shared Cancer Dataset Analysis Identifies and Predicts the Quantitative Effects of Pan-Cancer Somatic Driver VariantsJakob Landau, Linoy Tsaban, Adar Yaacov, et al.
Cell Reports. Medicine|June 12, 2024
Cancer mutational signatures identification in clinical assays using neural embedding-based representationsAdar Yaacov, Gil Ben Cohen, Jakob Landau, et al.
Frontiers in Medicine|July 13, 2026
Dynamics in kidney function markers as predictors of post-ICU survival: an innovative approach to enhance marker accuracyJakob Landau, Irene Unterman, Keren Tzukert, et al.
Computers in Biology and Medicine|December 19, 2024
Graph convolution networks model identifies and quantifies gene and cancer specific transcriptome signatures of cancer driver eventsGil Ben Cohen, Adar Yaacov, Yishai Ben Zvi, et al.
Journal of Lipid Research|August 8, 2019
In search of a genetic explanation for LDLc variability in an FH family: common SNPs and a rare mutation in <i>MTTP</i> explain only part of LDL variability in an FH familyMichael Winther, Shoshi Shpitzen, Or Yaacov, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Biomedicines|November 27, 2025
Employing an Artificial Intelligence Platform to Enhance Treatment Responses to GLP-1 Agonists by Utilizing Metabolic Variability Signatures Based on the Constrained Disorder PrincipleJakob Landau, Yariv Tiram, Yaron Ilan
Cancer Research|October 20, 2022
Shared Cancer Dataset Analysis Identifies and Predicts the Quantitative Effects of Pan-Cancer Somatic Driver VariantsJakob Landau, Linoy Tsaban, Adar Yaacov, et al.
Cell Reports. Medicine|June 12, 2024
Cancer mutational signatures identification in clinical assays using neural embedding-based representationsAdar Yaacov, Gil Ben Cohen, Jakob Landau, et al.
Frontiers in Medicine|July 13, 2026
Dynamics in kidney function markers as predictors of post-ICU survival: an innovative approach to enhance marker accuracyJakob Landau, Irene Unterman, Keren Tzukert, et al.
Computers in Biology and Medicine|December 19, 2024
Graph convolution networks model identifies and quantifies gene and cancer specific transcriptome signatures of cancer driver eventsGil Ben Cohen, Adar Yaacov, Yishai Ben Zvi, et al.
Journal of Lipid Research|August 8, 2019
In search of a genetic explanation for LDLc variability in an FH family: common SNPs and a rare mutation in <i>MTTP</i> explain only part of LDL variability in an FH familyMichael Winther, Shoshi Shpitzen, Or Yaacov, et al.
Pageof 1